Machine learning to tell apart two rare diseases
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial uses computer models (machine learning) to help doctors better distinguish between two rare conditions that both cause high levels of a certain white blood cell (eosinophil). The goal is to make diagnosis faster and more accurate, which could lead to more targeted treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have been diagnosed with either EGPA (a type of blood vessel inflammation) or HES (a syndrome with very high eosinophil levels).
- You can provide written consent, or have a friend or family member give assent if you have physical disabilities that prevent you from doing so.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry study looks at adults with high eosinophils (a type of immune cell) that are believed to be causing damage in the airways or lungs. It aims to better identify these eosinophils and understand what is going on so future treatments can improve.
This study uses advanced genetic testing to see if they can predict how monoclonal gammopathies (early blood conditions that may turn into cancer) will change over time. It may help doctors understand your risk better.
This trial uses genetic testing to find the cause of rare kidney diseases. It is for people with unexplained kidney problems, a family history of kidney disease, or certain findings on ultrasound. The goal is to provide a more personalized diagnosis and see if this approach is cost-effective.
This study looks at different types of eosinophils (a type of white blood cell) in people with asthma, EGPA, or HES. It aims to help doctors better understand these conditions and could guide future treatments.
This trial tests a medicine called benralizumab for children with specific eosinophil-driven diseases (EGPA or HES). It aims to see if the drug can help control these conditions.
This study follows people with long-term high eosinophils (a type of white blood cell) and related conditions to learn how the illness changes over time. It helps doctors understand patterns of organ involvement and outcomes, which may improve future care.
Hear when a new EGPA - Eosinophilic Granulomatosis With Polyangiitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.